Skip to NavigationSkip to content

Pharmafile - Sales and Marketing News

The FDA has chosen to expand the indications of Pfizer’s Ibrance (palbociclib), the company announced, approving the CDK4/6 inhibitor in...
NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to...
Sorrento Therapeutics is seeking $1 billion in damages from billionaire biotech investor Patrick Soon-Shiong, owner of US newspaper the LA Times.
The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a...
Sangamo Therapeutics and Pfizer have unveiled new Phase 1/2 data for their jointly developed investigational gene therapy SB-525, demonstrating...
Novartis has revealed that its interleukin-17A (IL-17A) Cosentyx (secukinumab) has been authorised for use in China in the treatment of moderate-to...
Teva has announced that its calcitonin gene-related peptide (CGRP) inhibitor Ajovy (fremanezumab) has been awarded marketing authorisation by the...
Massachusetts-based bluebird bio has taken a significant leap forward in its pursuit of regulatory authorisation for its first gene therapy,...
Indian authorities in the state of Rajasthan have said that samples taken from Johnson & Johnson’s baby shampoo contained ‘harmful ingredients.’
Swiss firm Novartis has agreed to pay a sum of $310 million upfront to Boston inflammation specialist IFM Therapeutics, as part of a deal worth...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches